The Dysmenorrhea drugs in development market research report provides comprehensive information on the therapeutics under development for Dysmenorrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Dysmenorrhea. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Dysmenorrhea and features dormant and discontinued products.
GlobalData tracks five drugs in development for Dysmenorrhea by five companies/universities/institutes. The top development phase for Dysmenorrhea is phase i with three drugs in that stage. The Dysmenorrhea pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Dysmenorrhea pipeline products market are: Dare Bioscience, Fuji Pharma and Overseas Pharmaceuticals.
The key targets in the Dysmenorrhea pipeline products market include Prostaglandin G/H Synthase 2 (Cyclooxygenase 2 or COX2 or Prostaglandin Endoperoxide Synthase 2 or PHS II or Prostaglandin H2 Synthase 2 or PTGS2 or EC 1.14.99.1), Prostaglandin G/H Synthase 1 (Cyclooxygenase 1 or COX1 or Prostaglandin Endoperoxide Synthase 1 or Prostaglandin H2 Synthase 1 or PTGS1 or EC 1.14.99.1), and Progesterone Receptor (Nuclear Receptor Subfamily 3 Group C Member 3 or NR3C3 or PGR).
The key mechanisms of action in the Dysmenorrhea pipeline product include Prostaglandin G/H Synthase 2 (Cyclooxygenase 2 or COX2 or Prostaglandin Endoperoxide Synthase 2 or PHS II or Prostaglandin H2 Synthase 2 or PTGS2 or EC 1.14.99.1) Inhibitor with three drugs in Phase I. The Dysmenorrhea pipeline products include two routes of administration with the top ROA being Oral and one key molecule types in the Dysmenorrhea pipeline products market including Small Molecule.
Dysmenorrhea overview
Dysmenorrhea is the medical term for painful menstrual periods. It happens when uterus contracts to shed its lining. The pain typically begins just before your period and subsides after a few days. Primary dysmenorrhea refers to recurrent pain with no identifiable cause. Secondary dysmenorrhea results from conditions like endometriosis
For a complete picture of Dysmenorrhea’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
